INVOLIN

Dead / Cancelled — Cancelled — Section 8 (as of 30 Dec 2011)

What this means for you

This registration has been cancelled; it no longer blocks anyone on its own. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.

Record

Serial number
76307432
Registration number
2954070
Mark type
Word mark
Filed
30 Aug 2001
Published for opposition
04 May 2004
Registered
24 May 2005
Attorney of record
Barry L. Kelmachter

Goods and services

  • Class 001 — Chemicals: chemical, biochemical, biotechnological products intended for industry, the sciences, agriculture, and horticulture, namely polypeptides for in vivo and in vitro genetic engineering, natural and engineered meganucleases and endonucleases, nucleic acid vectors, and molecular scissors, and ready to use genomic recombination systems primarily composed of DNA reagents and endonucleases for scientific research use; cells engineered by meganuclease recombination systems for scientific, laboratory or medical research; chemical, biochemical, biotechnological and bacteriological products intended for research laboratories and control laboratories, namely polypeptides for in vivo and in vitro genetic engineering, natural and engineered meganucleases and endonucleases, nucleic acid vectors, and molecular scissors, and ready to use genomic recombination systems primarily composed of DNA reagents and endonucleases for scientific research; deoxyribonucleic acid reagents for scientific research use, namely for the transport of biological molecules; microorganism cultures and preprations for use in the manufacture of human and veterinary pharmaceuticals, namely microorganisms engineered by meganuclease recombination systems, microorganisms producing polypeptides for in vivo and in vitro genetic engineering, natural and engineered meganucleases and endonucleases, nucleic acid vectors, molecular scissors, and ready to use genomic recombination systems primarily composed of DNA reagents and endonucleases; microorganisms used for producing therapeutic compounds or vaccines; microorganism cultures and preparations for medical research use, namely microorganisms engineered by meganuclease recombination systems, microorganisms producing polypeptides for in vivo and in vitro genetic engineering, natural and engineered meganucleases and endonucleases, nucleic acid vectors, molecular scissors, and ready to use genomic recombination systems primarily composed of DNA reagents and endonucleases; bacteriological preparations for medical research use, namely bacteriological preparations engineered by meganuclease recombination systems, bacteriological preparations producing polypeptides for in vivo and in vitro genetic engineering, natural and engineered meganucleases and endonucleases, nucleic acid vectors, molecular scissors, and ready to use genomic recombination systems primarily composed of DNA reagents and endonucleases; bacteriological preparations for use in the manufacture of human and veterinary pharmaceuticals, namely bacteriological preparations engineered by meganuclease recombination systems, bacteriological preparations producing polypeptides for in vivo and in vitro genetic engineering, natural and engineered meganucleases and endonucleases, nucleic acid vectors, molecular scissors, ready to use genomic recombination systems primarily composed of reagents and endocnuclease
  • Class 005 — Pharmaceuticals: Pharmaceutical, veterinary and health-care products, namely polypeptides for in vivo and in vitro genetic engineering for clinical use; natural and engineered meganucleases and endonucleases, nucleic acid vectors, molecular scissors, and ready to use genomic recombination systems primarily composed of DNA reagents and endonuclease for clinical use; cells engineered by meganuclease recombination systems for clinical use; microorganism cultures and preparations for clinical medical use, namely microorganisms engineered by meganuclease recombination systems, natural and engineered meganucleases and endonucleases, and nucleic acid vectors; microorganism cultures and preparations for use as human and veterinary pharmaceuticals, namely microorganisms engineered by meganuclease recombination systems, natural and engineered meganucleases and endonucleases, nucleic acid vectors, molecular scissors, and ready to use genomic recombination systems primarily composed of DNA reagents and endonucleases, and microorganisms used for producing therapeutic compounds or vaccines; bacteriological preparations for clinical medical use, namely bacteriologic preparations engineered by meganuclease recombination systems, natural and engineered meganucleases and endonucleases and nucleic acid vectors; bacteriological preparations for use as human and veterinary pharmaceuticals, namely bacteriological preparations engineered by meganuclease recombination systems, natural and engineered meganucleases and endonucleases, nucleic acid vectors, molecular scissors, and ready to use genomic recombination systems primarily composed of DNA reagents and endonucleases; drugs for clinical medical use, namely polypeptides for in vivo and in vitro genetic engineering, natural and engineered meganucleases and endonucleases, nucleic acid vectors, and molecular scissors; drugs for use as human and veterinary pharmaceuticals, namely polypeptides for in vivo and in vitro genetic engineering, natural and engineered meganucleases and endonucleases, nucleic acid vectors, and molecular scissors; biological preparations for clinical medical use, namely polypeptides for in vivo in vitro genetic engineering, natural and engineered meganucleases and endonucleases, nucleic acid vectors, molecular scissors, ready to use genomic recombination systems primarily composed of DNA reagents and endonucleases, and cells engineered by meganuclease recombination systems; drugs for use as human and veterinary pharmaceuticals, namely polypeptides for in vivo and in vitro genetic engineering, natural and engineered meganucleases and endonucleases, nucleic acid vectors, molecular scissors, ready to use genomic recombination systems primarily composed of DNA reagents and endonucleases, and cells engineered by meganuclease recombination systems; chemical biochemical preparations for clinical medical use, namely polypeptides for in vivo and in vitro genetic engineering, natural and engineered meganucleases and endonucleases, nucleic acid vectors, molecular scissors, ready to use genomic recombination systems primarily composed of DNA reagents and endonuclease, and cells engineered by meganuclease recombination systems; chemical and biochemical preparations for use as human and veterinary pharmaceuticals, namely polypeptides for in vivo and in vitro genetic engineering, natural and engineered meganucleases and endonucleases, nucleic acid vectors, molecular scissors, ready to use genomic recombination systems primarily composed of DNA reagents and endonucleases, and cells engineered by meganuclease recombination systems; chemopharmaceutical products
  • Class 042 — Scientific and technological services: Scientific and industrial research; research in genetic, medical, pharmaceutical, veterinary, botanic and microbiological fields; research in chemistry, biology, biochemistry, molecular biology, and bacteriology; research and development for others of techniques of biochemical analysis, biological analysis, and molecular biology techniques; scientific transgenesis research of deoxyribonucleic acid for the preparation or conveying of biological molecules; scientific analysis namely in genetic, medical, pharmaceutical, veterinary, botanic and microbiological fields; research and development for others of new molecules intended for industry; laboratory research in the fields of biotechnology, human and veterinary medicine, genetic engineering, protein design, drug design, genetic therapy, molecular biology, and agriculture; medical services; studies of technical projects in the field of biotechnology, human and veterinary medicine, genetic engineering, protein design, drug design, genetic therapy, molecular biology, and agriculture; testing, analysis and evaluation of engineering works for others; licensing of patents and intellectual property; computer programming for others, development for others of multimedia software programs

Owner

Prosecution history

  • 30 Dec 2011 — CANCELLED SEC. 8 (6-YR)
  • 24 May 2005 — REGISTERED-PRINCIPAL REGISTER
  • 25 Mar 2005 — OPPOSITION TERMINATED NO. 999999
  • 25 Mar 2005 — OPPOSITION DISMISSED NO. 999999
  • 09 Sept 2004 — OPPOSITION INSTITUTED NO. 999999
  • 02 Jun 2004 — EXTENSION OF TIME TO OPPOSE RECEIVED
  • 04 May 2004 — PUBLISHED FOR OPPOSITION
  • 14 Apr 2004 — NOTICE OF PUBLICATION
  • 10 Feb 2004 — APPROVED FOR PUB - PRINCIPAL REGISTER
  • 08 Oct 2003 — CORRESPONDENCE RECEIVED IN LAW OFFICE
  • 18 Oct 2003 — CASE FILE IN TICRS
  • 08 Oct 2003 — FAX RECEIVED
  • 03 Oct 2003 — CONTINUATION OF FINAL REFUSAL MAILED
  • 16 Sept 2003 — PREVIOUS ACTION COUNT WITHDRAWN
  • 15 Sept 2003 — PREVIOUS ALLOWANCE COUNT WITHDRAWN

View this trademark record on Marksy